StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie humira (adalimumab) — International reported growth YoY (%) (%)

Form 8-K Key Product Revenues Schedule

Latest, FY2025
-20.2%
Period ended Dec 31, 2025
Change on a year earlier
-2.7 pts
-17.5% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedHumira (adalimumab) — International reported growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 2025-20.2%-2.7 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
FY2024Dec 31, 2024-17.5%-3.2 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
FY2023Dec 31, 2023-14.3%+7.9 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
FY2022Dec 31, 2022-22.2%-12.6 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
FY2021Dec 31, 2021-9.6%+4.0 ptsForm 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
FY2020Dec 31, 2020-13.6%+14.2 ptsForm 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗
FY2019Dec 31, 2019-27.8%-28.4 ptsForm 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗
FY2018Dec 31, 20180.6%-6.1 ptsForm 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗
FY2017Dec 31, 20176.7%–Form 8-K (abbv-20171231xexhibit991.htm, filed 2018-01-26) ↗

Cite this data

StockData. (2026). AbbVie Humira (adalimumab) — International reported growth YoY (%) (%), annual FY2017–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/humira_intl_rep_yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.